Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GlaucoCetin
- Development stage
- Preclinical
- Lead developer
- Guardion Health Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GlaucoCetin is an oral proprietary medical food and nutraceutical formulation developed by Guardion Health Sciences for patients with open-angle glaucoma. It is described as an enhanced successor to GlaucoHealth and is intended to support optic nerve and retinal ganglion cell health by addressing mitochondrial dysfunction and oxidative stress, with the goal of neuroprotection in glaucoma. Based on the provided context, the formulation includes nicotinamide and is part of a broader multi-ingredient ocular health supplement strategy rather than a conventional small-molecule or biologic pharmaceutical.
- Brand names
- GlaucoCetin
Beyond the preview
Go deeper on GlaucoCetin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GlaucoCetin.